Merck & Co., the second-biggest U.S. drugmaker, said cholesterol treatments Vytorin and Zetia failed to win approval to prevent heart attacks and strokes in patients with chronic kidney disease. Vytorin is a combination of Zetia and Zocor, or simvastatin, and has been available in generic form since 2006.
FDA Turns Down Expanded Use of Merck’s Vytorin and Zetia
Published January 25, 2012 News Leave a CommentTags: FDA, Food and Drug Administration, Vytorin, Vytorin and heart attacks, Vytorin and kidney disease, Vytorin and strokes, Zetia, Zetia and heart attacks, Zetia and kidney disease, Zetia and strokes
0 Responses to “FDA Turns Down Expanded Use of Merck’s Vytorin and Zetia”